Kawano Jordan, Arora Rohit
Department of Medicine, Chicago Medical School, North Chicago, IL 60064, USA.
J Cardiometab Syndr. 2009 Winter;4(1):44-9. doi: 10.1111/j.1559-4572.2008.00030.x.
Nearly 1 in 4 adults in the United States is obese. The connection between obesity and insulin resistance, type 2 diabetes, and cardiovascular disease is a well researched one. The increasing prevalence of each of these diseases has become a growing concern for the medical community. Adiponectin is a collagen-like plasma protein secreted by adipocytes that has been suggested to play a causal role in the development of insulin resistance and cardiovascular disease. The protein has been found to be decreased in cases of insulin resistance, diabetes, atherosclerosis, and coronary artery disease. Up-regulation of adiponectin and its receptor, through the use of thiazolidinediones, has been found to be partially related to insulin sensitization and thus antidiabetic effects. In this review, we discuss adiponectin's antiatherogenic effects, its association with insulin resistance and obesity, and the possibility of using adiponectin and its receptor as a therapeutic target.
在美国,近四分之一的成年人患有肥胖症。肥胖与胰岛素抵抗、2型糖尿病和心血管疾病之间的联系已得到充分研究。这些疾病的患病率不断上升,已成为医学界日益关注的问题。脂联素是一种由脂肪细胞分泌的类胶原蛋白血浆蛋白,有人认为它在胰岛素抵抗和心血管疾病的发展中起因果作用。已发现该蛋白在胰岛素抵抗、糖尿病、动脉粥样硬化和冠状动脉疾病患者中含量降低。通过使用噻唑烷二酮类药物上调脂联素及其受体,已发现这与胰岛素增敏作用以及抗糖尿病作用部分相关。在本综述中,我们讨论了脂联素的抗动脉粥样硬化作用、其与胰岛素抵抗和肥胖症的关联,以及将脂联素及其受体用作治疗靶点的可能性。